Do you follow our Newsletter? Sign up here!
The latest news
Nanexa doses the first patient in the 30 mg dose group in the phase I study with NEX-22. Read more.
Boule Diagnostics announces closure of the BM950 project and new portfolio strategy. Read more.
intends to carry out a directed issue of shares of approximately SEK 20 million. Read moreThe issue has been completed. Read more.
AcouBlack exploring opportunities in South Korea at the KIMES trade fair. Read more.
Prolight Diagnostics announces that Psyro's pilot production line of test cards reaches another milestone. Read more.
Lundbeck's Rxulti (brexpiprazole) has been approved in the EU for the treatment of schizophrenia in adolescents aged 13 years and older. Read more.
NextCell Pharma announces that results from the age group in the ProTrans-Young pediatric study are expected in April. Read more.
Attana announces that leading healthcare institutions in the US are extending service and support contracts. Read more.
Nightingale Health applies for listing of its B shares on the Nasdaq Helsinki main market. Read more.
Flagging message in OrionBlackRock Inc has increased its ownership in the company to over 5 percent. Read more.
Summons
Bavarian Nordic Getinge Scandion Oncology
Communiqués
ADDvise Group Embla Medical FluoGuide Genmab
Insider trading
Reports
Biovica oriola Phase Holographic Imaging Scandion Oncology
The latest from BioStock
» Saniona's new CMO: "More deals are definitely on the horizon"
» Boule Diagnostics scraps its own development
» Peptonic Medical files for reorganization
» BioStock Investor Pitch: Annexin Pharmaceuticals
» Enzymatica's results are published in The Journal of Physiology